March 14 (Reuters) - AstraZeneca Plc said on Monday the U.S. Food and Drug Administration (FDA) rejected its asthma medicine, Fasenra, for treatment of chronic rhinosinusitis with nasal polyps, a condition where benign growths can cause pain and stuffiness.

The London-listed drugmaker said the FDA had issued a complete response letter following its application to extend use of the drug and requested additional clinical data from AstraZeneca. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Rashmi Aich)